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ABSTRACT 
Contributions to Peptidomimetic Design: 
Predictive Computational Studies and  
Syntheses of Linker Molecules. 
(December 2005) 
Sang Q. Lam, B.S., The University of Texas at Dallas 
Chair of Advisory Committee: Dr. Kevin Burgess 
 
 In an effort to partially mimic the complex interaction between nerve growth 
factor (NGF) and its membrane-bound tyrosine kinase A receptor (TrkA), several small 
organic molecules with functionalities similar to the side-chains of the amino acid 
residues of NGF critical to binding were devised. These molecules were studied 
computationally using the program Affinity. Each molecule was individually docked onto 
one of the binding sites on TrkA as determined by mutagenesis studies and the x-ray 
crystal structure obtained from the Protein Data Bank. 
 One of the strategies to enhance binding of active peptidomimetics to their target 
proteins is to link them together to form either homodimers or heterodimers. However, 
these dimers have low solubility in water and mimic only residues that are close together 
on the protein. Triethylene oxide- and hexaethylene oxide-based linker molecules were 
designed to circumvent these limitations. The increased polarity will improve the water-
solubility and the added lengths, which can be controlled and varied by simple chemical 
manipulations, will allow for mimicking critical residues that are farther apart on the 
protein.     
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CHAPTER I 
INTRODUCTION TO PROTEIN-PROTEIN INTERACTIONS AND 
PEPTIDOMIMETICS 
1.1 Protein-Protein Interactions 
Proteins are ubiquitous macromolecules that play key roles in biological processes 
ranging from catalysis of chemical reactions to providing structural support of cells to the 
transcription of deoxyribonucleic acid (DNA).  Central to the intrigue of proteins is how 
they interact with one another.  Although the proteins primary, secondary, tertiary, and 
quaternary structural forms are important to how they interact with one another, only the 
primary and secondary structures are generally targets for mimicry.  This thesis will focus 
on the mimicry of the proteins secondary structural forms, particularly the α-helix in the 
chapter II.  Linus Pauling and Robert Corey, through their exhaustive x-ray diffractive 
studies of fibrous proteins, generalized the protein structures as falling into three 
secondary types: the α pattern, the β pattern, and the collagen pattern.1  
1.1.1 Protein Secondary Structures: α-Helices and β-Turns 
The secondary motifs that seem to recur often in mediating protein-protein 
interactions are the α helices and β turns (Figure 1.1).2,3  The R-, L-, and 3.10 α−helices 
and the type I and type II β turns are of particular interest because of their well-known 
status in the literature.  The R and L denote whether the helix is coiling to the right or 
left, respectively, and the 3.10 denotes 3 residues per turn of the helix, a total of 10 atoms 
from the oxygen of the carbonyl group (hydrogen bond donor) of the i residue to the 
hydrogen of the amide group (hydrogen bond acceptor) of the i + 3 group.4  A type I β 
turn has the carbonyl oxygen from the amide bond between the i + 1 and i + 2 oriented 
away from the observer while in a type II turn it is oriented toward the observer.5  
 
__________________ 
This thesis follows the style of the Journal of American Chemical Society. 
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Figure 1.1 (A) General structure of an α helix (naturally occurring R-α helix shown). 
Each turn of the helix incorporates 3.6 residues. (B) General structure of a β turn.  
 
1.1.2 “Hot Spots” at Protein-Protein Interfaces 
Nussinov and coworkers define a protein-protein interface as an area, within a 
distance threshold, of interacting amino acid residues between at least two protein 
chains.6  Precisely which residues constitute an interface varies from study to study.7 
Interface areas are calculated based on crystal structures of monomeric proteins and 
complexed proteins.  In the complexed state, a certain percentage of the total area is 
“buried” by the interaction.  This interface area was found by Janin and coworkers7,8 to 
be from 670 to 4890 Å2 while Jones and Thornton7 discovered a slightly wider range, 
from 368 to 4761 Å2.  Within these interfaces there often exist critical binding points 
known as hot spots.  Although no predictions can be made with regard to whether or not 
particular sites are hot spots, polar residues do tend to be conserved at these sites.6,9  X-
ray crystallography revealed that hot spots are highly structural with side chains of amino 
acid residues from one surface fitting into the cavities and crevices on the opposite 
surface.10  These residues are so important in binding that when mutated to alanine cause 
a dramatic decrease in the binding constant, usually tenfold or higher.11  
 
  
 
NH
R
HN
O
R1
CO
H
N
R2
HN
O
R3
O
(A) (B)i
i
i + 1
i + 1
i + 2
i + 2
i + 3
i + 3
i + 4
i + 5
5.4 Å
 3 
1.2 Peptidomimetics 
As the name implies, peptidomimetics are organic molecules that mimic the 
action of peptides.  These molecules may structurally resemble peptides but are distinctly 
different in terms of their side chains or their molecular backbones.  Since the mode of 
action for a small-molecule and a peptidomimetic is similar, confusion sometimes arises 
with regard to the classification of the molecule as being a peptidomimetic or simply a 
small organic molecular mimic.  Nevertheless, interactions with proteins can be mediated 
by other molecules with intermediate molecular masses instead of the low molecular 
weights associated with small-molecules or peptidomimetics. 
 
1.2.1 Small Molecules Mediating Protein-Protein Interactions 
Mimicking or disrupting protein-protein interactions using small molecules is a 
well-known topic in the literature.  Comprehensiveness of the subject is by no means the 
theme of this section.  Instead, a few recent examples significant in the areas of cancer 
research and immunology will be presented.  In vitro and in vivo evidence has shown that 
cancerous cells that metastasize depend on selectin-, integrin-, and chemokine-mediated 
vascular adhesion events.12  It was recently discovered that the chemokine receptor 
CXCR4 was involved in attracting tumor metastases to the bone marrow, and that 
AMD3100, a small molecule antagonist, binds the receptor thereby preventing the spread 
of the tumor to the site.12,13  On a similar note, a mimic of the second mitochondria-
derived activator of caspases (Smac), a protein involved in apoptosis, was just as 
effective as the native ligand at 105 to 106-fold lower concentrations.14  The mannose-
binding lectin (MBL) plays a very important role in the lectin complement pathway 
which is responsible for the development of the immune response in early childhood and 
the inflammatory response on oxidatively stressed endothethial cells.15  A decapeptide 
with the sequence SFGSGFGGGY was found to mimic the known ligand of MBL, N-
acetyl-D-glucosamine (GlcNAc).15  Arguably one of the most extensively studied and 
important biological interactions are those between integrins and cell adhesion molecules 
(CAMs).16-18  Integrins are a large family of heterodimeric (consisting of an α subunit 
and a β subunit) surface receptors on cellular plasma membranes that mediate cell-matrix 
and cell-cell interactions.17,18  Thus far, the protein-protein interactions antagonized by 
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small molecules that involve integrins, intracellular adhesion molecules (ICAMs), and 
vascular cellular adhesion molecules (VCAMs) known are αvβ3/vitronectin, αvβ3/MMP2, 
VLA4/VCAM, and LFA-1/ICAM.19,20,21  BXT-51072, a glutathione peroxidase (GPx) 
mimic, has been shown to inhibit ICAM-1 and VCAM-1 expressions by tumor necrosis 
factor-α (TNFα).22  Since the discovery of the residues within ICAM-1 that are important 
for the interaction with LFA-1, Gadek and co-workers developed a LFA-1 antagonist 
with an IC50 of 1.4 nM.23  Figure 1.2 shows the structures of all the small molecules 
mentioned above.      
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Figure 1.2 Small molecules that mimic or disrupt protein-protein interactions. 
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1.2.2 α-Helix and β-Turn Peptidomimetics 
As mentioned earlier in the thesis, α helices and β turns are among the most 
abundant secondary structures that can be found mediating protein-protein interactions.  
As with all conceptual designs, the target protein serves as the model which fuels 
innovations.  The target selected for the discussion in this thesis is nerve growth factor 
(NGF), a neurotrophin with some hot spots identified to be β turns and α helices.24-26 
Details about the hot spots, its crystal structure and related neurotrophins will be covered 
in chapter II.  This section will briefly touch upon the various published designs of α 
helix and β turn peptidomimetics.  Figure 1.3 shows a couple of specific peptidomimetic 
examples that are neither α helix nor β turn mimics, but are potent inhibitors of herpes 
virus16 and adenovirus.27  Figure 1.4 depicts examples of β turn peptidomimetics that  
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Figure 1.3 (A) Herpes virus ribonucleotide reductase inhibitor. (B) Adenovirus inhibitor. 
 
have been published in the literature.28-35  Of particular interest is the Burgess design  
which provided useful lead compounds, D3 and MPT18, each of which binds TrkA and  
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Figure 1.4 β turn peptidomimetic designs from various research groups. 
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Figure 1.5 β turn peptidomimetics that bind tyrosine kinase A and C receptors. 
 
TrkC respectively (Figure 1.5).25,30  Designing peptidomimetics to mimic the behavior of 
α helices are much more difficult as most of the designs are more prone to conform-
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ational changes than those for β turns.  Nevertheless, successful attempts have been made 
and published (Figure 1.6).3,36-41  The distances between the residues in the α-helices 
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Figure 1.6 Terphenyl, biphenyl, and indane as α-helical mimetics. 
 
Table 1.1 Distances between residue i and residue i + n in an α-helix. 
 
 
Residue, n Distance from i,  ( Å ) 
1 4.70 
2 7.94 
3 7.89 
4 7.81 
5 10.60 
6 12.58 
7 12.81 
8 14.13 
9 16.63 
10 17.92 
 
 
are unique in a sense that the distance between i  and i + n are not necessarily larger than 
the distance between i and i + (n – 1).  For instance, Table 1.1 shows that from i to i + 3 
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is 7.89 Å and from i to i + 2 is 7.94 Å for an α-helix.  Since the distances vary slightly 
between R- and L-α helices, the distances shown in the table are averages.  In addition, 
the helices were constructed using only alanine amino acids, and all the measurements 
were taken from the α carbons between the residues.  
1.3 Summary 
Mimicking protein-protein interactions poses a very challenging feat in medicinal 
chemistry.  To be considered effective, a small-molecule or peptidomimetic must, at the 
least, interact with the protein in a way that is similar to the native ligand. Three factors 
need consideration before embarking on the task of designing such a molecule: the 
comparable binding orientation of the molecule with the native ligand, the synthetic 
feasibility of the designed molecule, and the binding strength. 
Chapter II of this thesis will discuss the details of using molecular modeling to 
compare how a set of designed molecules, mimicking the N-terminus of NGF, interact 
with tyrosine kinase A (TrkA) receptor.  Synthetic ease of the designed molecules were  
considered but not proven experimentally.  Since the compounds were not synthesized, 
no binding constants were determined. 
Chapter III will discuss the design and syntheses of linker molecules with variable 
lengths that have the capabilities of spanning the various distances between hot spots on a 
protein.  Peptidomimetics could be attached to these linkers and then anchored to a core 
molecule, thereby creating bivalent molecules with potential for enhanced affinities.  
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CHAPTER II 
PREDICTIVE COMPUTATIONAL STUDIES OF DESIGNED 
MOLECULES MIMICKING THE INTERACTION OF THE N-
TERMINUS OF NGF AND TRKA 
2.1 Introduction to Structure-Based Drug/Ligand Design 
It is in no small part due to the structure-based design method that there are a 
plethora of drugs released nowadays on the market.  With the emergence of more 
powerful computers not to mention the wealth of 3-D structural data of proteins currently 
available for meticulous scrutiny, the method has become almost a standard protocol in 
the pharmaceutical industry for designing novel drugs.42,43  Effort and research are now 
underway to “fine-tune” the simulation of ligand-protein interactions, a process known as 
docking, and compare the result to natural systems from which it tries to emulate.44 
2.1.1 Overview of the Docking Method 
Assessing predictions of protein-protein interactions using the docking 
methodology is a complex and time-consuming process requiring collaborations between 
many research groups, such as the community-wide Critical Assessment of PRedicted 
Interactions (CAPRI) experiment.45  For most docking algorithms, however, a docking 
calculation usually involves three basic steps: prepare the system, that is, assign receptor 
and ligand potentials and create a docking assembly; perform the calculation, fill in 
parameters, set energy cut-offs, and launch the job; and analyze the results.45  In selecting 
what program to use, two factors need to be considered: parameterization and score 
functions.42-44  Parameterization refers to the set of parameters used to describe a 
molecule (such as bond lengths, bond angles, energy of bond types, etc.) and score 
functions refer to a set of conditions a program uses to either accept or reject a docking 
result, often comparing the free energy of binding (∆Go).42-44  There are many programs 
available to simulate docking, each one offers its unique approach and perspective.  It is 
important to note that most programs are search algorithms, designed to scour for 
molecular structures in known databases, such as the Chemical Abstracts (CA), the 
American Chemicals Directory (ACD), or the National Cancer Institute (NCI),46,47 that 
seem to dock well onto the receptor.  
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2.1.2 Docking Programs 
DOCK, CAVEAT, FLOG, GOLD, PRO_LIGAND, GROWMOL, and SPROUT 
are just some of the numerous programs currently available for in silico screening.48,49 
Although covering all of them is beyond the scope of this thesis, a couple of programs are 
worth mentioning. Among them, DOCK is the most popular.46,50,51  Created by Kuntz, it 
is a rigid body docking method that does not consider protein and ligand flexibility.44,52 
Given a receptor on a protein, DOCK generates hard spheres that conform to the shape of 
the receptor, identifies a scaffold by analyzing key contact points, and finally searches for 
a match in a known database (Figure 2.1).46,52  Unlike DOCK, the program CAVEAT53 
 
O
O
OH
O
receptor
 
 
Figure 2.1 Schematic representation of DOCK operation. 
 
operates initially on the assumption that the orientation and position of bonds take 
precedent over the placement of atoms.42,51  Like DOCK, it is a rigid body docking 
method, not accounting for the flexibilities of the protein and ligand.42  The mechanistic 
operation of CAVEAT is that it analyzes the receptor surface on a cell, establishes 
vectors that would correspond to bond orientations, and searches for compounds in the 
database with bonds matching the magnitude and direction of the vectors (Figure 2.2).42,53   
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cell
receptor
 
 
Figure 2.2 Schematic representation of CAVEAT operation. Compounds in blue are 
potential matches. The red compound is an exact match that the program overlooked. 
 
Although CAVEAT is quite fast,42 a conspicuous drawback is that potential target 
matches can sometimes be overlooked. 
2.1.3 Affinity 
Jointly developed by Accelrys and the DuPont Merck Pharmaceutical Company, 
Affinity is a molecular mechanics/grid method that employs a full molecular force field, 
thus allowing for a more accurate representation of the receptor-ligand interaction.45,54,55  
Other docking programs, such as DOCK, CAVEAT, and FLOG, are descriptor-based 
methods that utilize empirical rules taking into account only hydrogen bonding, 
hydrophobic interactions, and steric effects which, at times, may not be enough to 
describe an interaction accurately.45  An attractive feature of Affinity is that it allows the 
user to rigidify the “bulk” of the protein while allowing only the binding site and ligand 
to move, minimizing the energy during the docking process with a combination of Monte 
Carlo (MC)45,56,57 and Simulated Annealing (SA)45,58 methods.  In the MC method, the 
program takes a “random walk” to generate a new conformation, then either rejects or 
accepts it based on the energy as compared to the initial conformation.56,57  In the SA 
method, the program heats the molecules rapidly to a high temperature, usually 1000K, 
then cools them down slowly; with equilibration, there will be many “energetic states” to 
which the molecules will fall—many of which are local minima—but with the correct 
cooling rate one conformation will eventually “freeze out” which is the global minimum 
conformation.58  In short, while holding the majority of the protein rigid, Affinity makes 
use of MC and SA methods to dock a given ligand onto a given receptor (Figure 2.3).  
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For simplicity the “bulk” of the protein being held rigid is not shown in the figure.  
Affinity can only implement two force fields, Consistent 
   
ligand
receptor
minimized complex
 
 
Figure 2.3 Schematic representation of Affinity operation.  
 
Valence Force Field (CVFF) or Consistent Force Field, Second Generation (CFF91), in 
the docking procedure.45  CVFF was the force field used in the docking procedure so only 
the functional form of the potential energy for CVFF is shown below (Figure 2.4).45 
 
Epot = Σ Db [1− e −α (b − b0)] + Σ Hθ (θ − θ0)2 + Σ Hφ [1 + scos(nφ)] 
         +  Σ Hχχ2    + ΣΣ Fbb'  (b − b0) (b' − b'0) +  ΣΣ Fθθ'  (θ − θ0) (θ' − θ'0) 
         + ΣΣ Fbθ  (b − b0) (θ − θ0) + Σ Fφθθ' cosφ (θ − θ0) (θ' − θ'0) +  ΣΣ Fχχ'χχ'
 
         + Σ ε [(r*/r)12 − 2 (r*/r)6]  + Σ qqi/εrij
b θ φ
χ
χ
b b' θ θ'
θb φ χ'
(1) (2) (3)
(4) (5) (6)
(7) (8) (9)
(10) (11)
 
Figure 2.4 The potential energy equation for CVFF.  
 
The first nine terms are bonding terms, describing the vibrations of internal coordinates, 
and the tenth term and the eleventh term represent the 12-6 van der Waals and Coulombic 
electrostatics, respectively, both of which are nonbonding terms.45  To establish a 3-D 
grid surrounding the movable atoms, the potential of the rigid atoms due to a grid point p 
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in space is calculated using the 12-6 van der Waals potentials (Figure 2.5).45  Also shown 
in the figure is the procurement of the electrostatic potential at a point p in space.45   
 
φΑ (p) =    Σ
(Ajj)1/2
r12jpj
∋
rigid terms
φΒ (p) =    Σ
(Bjj)1/2
r6jpj
∋
rigid terms
φES (p) =    Σ
qj
εrjpj ∋ rigid terms
potentials for rigid atoms
due to a grid point p in space
electrostatic potential 
at point p in space
 
 
Figure 2.5 Potentials used to establish a 3-D grid around movable atoms in CVFF.  
 
The A and B represent repulsive and dispersive parameters, respectively, while rjp is the 
distance between atom j and point p in space.45  ES is the electrostatic potential and qj is 
the charge of atom j.45  
Although not as popular or fast as the programs mentioned earlier, Affinity has 
been used to dock inhibitors of proteins such as plasmepsin II59 and telomerase.60  
Despite its limited uses in the literature, it is by no means ineffective; in fact, Affinity can 
be used to further study ligands designed in programs such as LUDI, reanalyze 
complexes docked with other programs, or perform relatively accurate ab initio docking. 
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2.2 Mimetics Designed to Mimic the N-Terminus of NGF  
Several factors were kept in mind when designing peptidomimetics.  One of the 
most obvious is the need to keep the molecules simple, thus synthetically facile should 
the need to make them arise.  In addition, the designed compounds should take after 
molecular scaffolds often found in known drugs.  Therefore, if the compounds were 
found to be active, then perhaps they will exhibit low toxicity and high bioavailability 
reducing the time spent in clinical trials.   
2.2.1 Neurotrophins 
Neurotrophins (NTs) are a family of highly homologous (~50% homology) 
growth factors that include nerve growth factor (NGF), brain-derived neurotrophic factor 
(BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5), and neurotrophin-6 
(NT-6).61  X-ray crystallography revealed that these NTs share a common elongated 
shape with two pairs of twisted, antiparallel β-strands, three hairpin loops, and a cysteine-
knot, formed by three disulfide bonds, to stabilize the conformation (Figure 2.6).61  
 
 
Figure 2.6 Neurotrophin monomers, excluding NT-6, with loops 1-4 (L1-L4).  
 
These NTs are crucial in the development of axonal and dendritic growth, synaptic 
formations and connections, apoptosis of sensory neurons, and neurotransmitter release, 
thereby making them immensely important therapeutic targets for treating medical 
conditions such as pain, depression, obesity, learning, and memory.61,62  Despite their 
sequence homology, NTs elicit their action by binding to two classes of cell surface 
NGF BDNF NT-3 NT-4/5 
L1 
L2 
L4 
L3 C 
N 
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receptors, the p75 neurotrophin receptor and the tyrosine kinase receptors.25,61  All mature 
NTs bind the common p75 receptor with low affinity (Kd ~10–9 M) and bind the Trk 
receptors with higher affinity (Kd ~10–11 M ) and selectivity, that is NGF binds only to 
TrkA, BDNF and NT-4/5 bind only TrkB, and NT-3 has the propensity to bind to TrkC, 
though it can weakly bind to TrkA and TrkB (Figure 2.7).61,63,64  Binding to Trk receptors  
 
 
TrkA
TrkB
TrkC
NGF
NT-4/5
BDNF
NT-3
 
 
Figure 2.7 Interactions of neurotrophins with their specific tyrosine kinase receptors.  
 
promote cell survival and normal differentiation, while binding to p75 causes 
apoptosis.61,65,66  Figure 2.8 shows the structures of the Trk receptors and p75.   
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Figure 2.8 Structures of monomeric tyrosine kinase (Trk) receptors and monomeric p75 
receptor. Residues shown in TrkA were found to be critical to binding NGF.  
 
An interesting fact to note is that p75 inhibits apoptosis in its dimeric form, but once an 
NT dissociates it to monomer form, it induces apoptosis.65  The focus of this thesis, 
however, is on NGF and TrkA; more specifically, the entire effort and emphasis will be 
on the N-terminus of NGF interacting with TrkA.  
2.2.2 Small Molecules That Mimic or Disrupt NGF-TrkA Interactions 
Small molecules that mimic or disrupt NGF-TrkA interactions are by no means 
absent in the literature. In addition to the Burgess TrkA agonist, D3, mentioned in chapter 
I of this thesis, Figure 2.9 shows some of the reported small molecules that mimic or 
disrupt NGF-TrkA interaction.25,67-70   
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Figure 2.9 Small molecules that mimic or disrupt NGF-TrkA interaction. 
 
2.2.3 Molecular Modeling of Designed Molecules Based on the α-Helix Scaffold 
Accounting for nearly one-third of all known protein structures,71 the α-helix is 
definitely a vital structural motif for molecular design and organic syntheses.  Its 
prominence can be seen at interfaces in viral/bacterial proteins such as HIV-1 gp41, 
EcoR1, and human papillomaviruses (HPVs); in transcription factors such as 
homodimers of bHLH TF E47, Jun, and cancer-linked ESX and Sur-2/DRIP130; and in 
cellular proteins such as HER2/neu, Bcl-XL-Bak, and p53-MDM2.37,72-74  Alpha helical 
mimicry has been reviewed by Hamilton73 and Fairlie.75  
NGF has many points of contact with its receptor TrkA (Figure 2.10).24,25  β-turn 
peptidomimetics have been synthesized and tested in the Burgess group for many of the 
turn regions, that is loops 1, 2, and 4.25  However, no progress has been made towards 
mimicking the N-terminus of NGF, bearing in mind that it is a different secondary form.  
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Figure 2.10 Structure of NGF dimer partially interacting with two TrkA receptors. The 
X-ray crystal showing the complete interaction has not been solved. The residues that are 
critical for binding as determined by mutagenesis are shown for loop 1, 2, 4, and the N-
terminus.  
 
Constraining molecules into helix-type conformations are difficult.  Research groups 
have attempted to stabilize and constrain peptide mimics by using side-chain-to-side-
chain covalent bonds, typically using linkages between residues i to i + 4 or residues i to 
i + 7,76-78 and even using metal ions.79  In order to mimic NGF, the designed molecules 
must simulate histidine 4 (H4) and isoleucine 6 (I6) side-chains, since these are the most 
critical binding residues.24  H4 forms hydrogen bonds with serine 304 (S304) of TrkA 
and I6 fills a hydrophobic “canyon” on the TrkA surface (Figure 2.11).24  No special  
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Figure 2.11 Crystallographic structure of the NGF-TrkA interaction at the N-terminus of 
NGF. The helix of NGF consists of four residues but only the residues of interest, 
histidine and isoleucine (yellow sticks), are shown. In the box, TrkA is represented by the 
Connolly surface. 
 
attention was determined in advance to constrain the designed molecules into a helical 
conformation.  Instead, the molecules proposed are limited to one degree of freedom 
about the central axis of rotation by the introduction of an alkyne functionality with a 
general notion that the steric hindrance between the side-chains will cause the molecule 
to adopt a helical conformation.  Figure 2.12 shows the proposed molecules 
superimposed over the helical part of NGF and docked onto TrkA.  Molecules 1 and 2 are 
indole derivatives.  Indoles are attractive targets because they appear in many important 
natural products and are prominent in known drugs.80  Cyclopentadienone 3, furan 4, and 
pyrazolidine 5 derivatives are strikingly simple structurally, almost drug-like.  Biphenyl-
type compounds 6 and 7, utilizing triazines and pyrazolidines, were fathomed because of 
their structural intrigue and the synthetic routes to obtaining them could possibly be 
facile.  Diketopiperazines and their derivatives are well known in the literature.  Molecule 
8 was proposed because the chemical routes to procure it are easily accessible.  The 
figures show the proposed molecules superimposed over the helical part of NGF that 
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Figure 2.12 Designed molecules superimposed over the helical part of NGF containing 
H4 and I6 residues (blue sticks) and docked onto TrkA (Connolly surface). 
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Figure 2.12 continued. 
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Figure 2.12 continued. 
 
encompasses H4 and I6 (blue sticks).  The docking calculations of the molecules onto 
TrkA were performed using Affinity in the InsightII package by Accelrys, Inc., running 
on a UNIX-based silicon graphic workstation.  These calculations were executed in the 
gas phase (ε = 1) with no predetermined cutoff values for the van der Waals and 
electrostatic interactions.  All conformations were satisfactorily minimized with the 
maximum derivative of the potential energy less than 10–3 kcal/mol.  Since solvent was 
not involved, the conformations that resulted must be used strictly in a predictive manner 
and not taken to be a representation of reality. 
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2.3 Results and Discussion 
There are many factors that affect how strongly a certain protein would interact 
with another protein such as solvent accessible surface area (ASA), planarity, circularity, 
extent of hydrogen bonding, electrostatic and shape complementarities, and hydro-
phobicity.81  This thesis focuses more on electrostatic and shape complementarities. The 
minimized conformations are intended to be used in a qualitative sense rather than a 
quantitative sense, that is to say a decision about whether or not a designed molecule is a 
mimic depends upon how its docked image appear and not what the numbers say about it.  
With that in mind, the docking results could easily be interpreted.  By comparing how 
well the side-chains of the designed molecules matched the side-chains of H4 and I6 of 
NGF in terms of both orientation and distance, compounds 1, 2, 4, and 5 emerged as 
primed candidates.  After analyzing the docked structures, only compound 1 arose as a 
potential α-helical mimic of the N-terminus of NGF, matching nearly perfectly with the 
crystal structure in Figure 2.11.  
On an interesting exploratory tangent, the designed molecules above could be 
used in the program LigandFit from the Cerius2 software suite.82  This algorithm differs 
from Affinity in that the entire receptor protein is held rigid while only the ligand is 
flexible.82  The uniqueness of the program lies in the fact that it can “predict” the hot 
spots by evaluating the terrain of a given protein surface, calculating whether or not the 
cavities and crevices are suitable for occupation.82  Therefore, the program has the 
potential of uncovering new sites of binding for a particular protein quickly without the 
need for experimentation.  The designed molecules may be able to dock onto these new 
sites.  However, preliminary work could not carried out because the program was not yet 
available. 
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CHAPTER III 
DESIGN AND SYNTHESES OF LINKING MOLECULES 
3.1 Multivalency in Biological Systems 
Whitesides defines the term valency of a molecule as the number of connections 
that it can form with other molecules through ligand-receptor-type interactions.83  
Therefore, mulitivalent molecules have the capacity to interact at multiple sites which 
make them useful in mediating cellular and enzymatic interactions.  After all, biological 
systems are complex entities.  The communication circuitries needed to sustain and 
maintain such systems are themselves complex, usually requiring multivalent binding. 
Multivalent ligands are highly versatile—they can act as agonists or antagonists—and 
can bind to selected targets with higher specificity and affinity.84,85 Although there are 
many multivalent scaffolds in the literature, the most common ones are low-molecular 
weight displays (dimers, trimers, etc.), dendrimers, polymers, and liposomes.84,85  The 
focus of this thesis is on low-molecular weight displays, mainly bivalency through 
dimerization.   
3.1.1 Dimerization Generalities  
Dimerization, allosteric conformational change, and receptor aggregation are the 
key mechanisms by which information is transmitted from the cell surface across the 
plasma membrane.86,87  Receptors for growth or differentiation factors are often activated 
by dimerization.87  It is no surprise then that this biological phenomenon has inspired 
synthetic organic chemists.  In fact, successful designs and syntheses of dimeric mimetics 
of various proteins are common in the literature.  Wrighton and co-workers demonstrated 
that a peptide mimetic of erythropoietin showed a 100-fold increase in binding affinity 
once it was dimerized.88  Schreiber and co-workers synthesized a dimer FK1012 from the 
monomer FK506 to study T–cell receptor (TCR) signaling pathways.89,90  Figure 3.1 
shows the structures of the erythropoietin mimetic and FK1012.  While the chemistry was 
not as important as the biological significance when these compounds were contrived,  
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Figure 3.1 Examples of mimetic dimers. βA-K represents a β-alanine/lysine linker. 
 
there are other examples in the literature where the emphasis is placed on the chemical 
means by which the dimers are constructed.  Schreiber and co-workers synthesized 
homo- and heterodimers of FMOC-amino acid and hydroxybenzaldehyde derivatives 
using cross-metathesis on solid support, a highly efficient and effective way to create 
libraries of diverse compounds (Figure 3.2).91  With the same goal of generating libraries  
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Figure 3.2 Example of a “serine dimer” synthesized by Schreiber. 
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for screening, Porco and co-workers recently produced a “oxime library” of heterodimers 
by ligating various alkoxyamine and carbonyl monomers through a process known as 
“chemical domain shuffling”.92  Biological screening against human small cell lung 
carcinoma (A549) cells revealed a dimer that inhibits growth with an IC50 value of  
6.2 µM (Figure 3.3).92  Boger and co-workers screened libraries for antiangiogenic  
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Figure 3.3 Schematic of chemical domain shuffling and the structure of the potent 
inhibitor of A549 cells that emerged from screening. 
 
molecules that would be more potent once they were “streamlined” to dimers.93  A dimer 
conceived from the tetramer A6B10C4 was discovered to have improved water-solubility 
and in vivo activity.93  The chemistry utilized to make the modifications was standard 
amide-bond construction chemistry (Figure 3.4).93  Deviating from the concept  
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Figure 3.4 Dimer construction by modification of tetrameric A6B10C4. 
 
of target-guided synthesis pioneered by Rideout almost 20 years ago, Sharpless and co-
workers screened for bivalent inhibitors by synthesizing them in situ from their 
monomeric parts.94  Monomeric alkyne and azides were situated into the active site—one 
monomeric partner at the peripheral site and the other partner at the active center—of 
Electrophorus electricus acetylcholinesterase (AChE) and “clicked” together by 
incubating at room temperature for 6 days.94  The result from the screen yielded syn-
TZ2PA6, an AChE inhibitor with a Kd value of 77 fM in Torpedo californica and a Kd 
value of 410 fM in murine AChE (Figure 3.5).94    
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Figure 3.5 In situ construction of dimer syn-TZ2PA6. Initially, monomer TZ2-6 would 
be placed in the active center and PA2-6 would be placed in the peripheral site of the 
AChE binding site. “Syn” refers to the 1,5-regioisomer (anti would be the 1,4-isomer).   
 
3.1.2 Burgess Method: Dimerizing Peptidomimetics Using Triazine as a Scaffold 
Cyanuric chloride (2,4,6-trichloro-1,3,5-triazine) is an attractive compound from a 
synthetic standpoint.  The chlorine atoms could easily be substituted successively with 
nucleophiles by varying the temperature.95  In fact, the simple chemistry allows easy 
generation of libraries, whether by solid-phase or solution-phase.96-98  Burgess and co-
workers have further demonstrated the utility of the triazine scaffold by the generation of 
a library of bivalent peptidomimetics to screen for binding of TrkA and TrkC.99  The 
syntheses were performed on solid-support using peptidomimetic monomers made in the 
group.99  Designed to be mimics of NGF and NT-3, the dimers were equipped with a 
fluorescein label to increase the solubility of the compounds and allow them to be 
detected easily by fluorescence activated cell sorting (FACS) assays.99  Although there 
were many hits from the screening, two homodimers emerged as having the highest 
fluorescence, dimers consisting only of I and dimers consisting only of II (Figure 3.6).99   
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Figure 3.6 Dimerizing peptidomimetics using the Burgess methodology. Homodimers of 
I bind TrkC, while homodimers of II bind TrkA.   
 
3.2 Triethylene and Hexaethylene Glycol-Based Linking Molecules 
Even though the fluorescein label helped the solubility of the dimeric peptide 
mimetics, solubility still remains a problem.  Low water-solubility causes difficulties in 
creating an assay to test them in addition to rendering them nearly useless as potential 
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pharmacophores in the drug discovery effort.  Attempts to modify the fluorescent tag by 
adding water-soluble functional groups such as sulfonic acids, carboxylic acids, and 
hydroxyl groups were unsuccessful and chemically impractical.  Not only were the 
modified fluorescent tags difficult to synthesize, they often exhibited unexpected and 
unwanted behavior—such as decomposition or lowered water solubility—when anchored 
to the triazine core.  Therefore, alternative approaches using triethylene glycols and 
hexaethylene glycols were explored to circumvent this problem.    
 
3.2.1 Triethylene Glycols (TEGs) and Hexaethylene Glycols (HEGs) 
Triethylene glycols and hexaethylene glycols have been widely-used molecules 
with applications that greatly vary in scope.  Ma and co-workers used both TEGs and 
HEGs as linker molecules in synthesizing RNA miniduplexes that retained their binding 
activities while being more resistant to higher temperatures, that is their denaturing 
temperature (Tm) increased by 24–31 oC.100  TEGs have been used in the synthesis of pi-
extended chromophores, with strong absorption in the UV/Vis region, that have a myriad 
of applications in materials science.101  On the other hand, HEGs have been used as 
linkers in the construction of non-nucleoside molecules that behave like RNA 
catalysts.102  More recently, HEG uses have extended into the syntheses of copolymers103 
and double hairpin helicates that bind divalent metal ions like copper.104  Water-solubility 
may increase up to 27-fold if TEGs or HEGs are incorporated into a desired system.105,106  
Thus, it is a plausible solution to the solubility problem discussed earlier (Figure 3.7).  
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Figure 3.7 A possible solution to the solubility of the Burgess dimeric mimetics. 
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3.2.2 Linker Designs  
Organic chemistry has many cycloaddition reactions involving heteroatoms at its 
disposal, such as hetero–Diels–Alder and 1,3-dipolar cycloadditions.  In their review of 
click chemistry, Sharpless and co-workers regarded the Huisgen dipolar cycloaddition of 
azides and alkynes as the “cream of the crop”.107  The recent interest can be attributed to 
the fact that 1,2,3-triazole derivatives have a wide range of applications, such as 
fungicides, herbicides, optical brightening agents, corrosion retardants, and 
pharmaceuticals.108  The reaction is robust, taking place in either aqueous or organic 
environments with a pH range from 4 to 12, and regioselective in the presence of 
copper(I), giving only 1,4-disubstituted 1,2,3-triazoles.109  Even with a series of 
publications adroitly demonstrating its simplicity and efficiency, Sharpless and co-
workers silenced any remaining critics with an elegant and imaginative synthesis of 
triazole dendrimers, perhaps the most significant impact with click chemistry recently 
published (Figure 3.8).110  Hii and co-workers recently developed a way to desymmetrize  
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Figure 3.8 Schematic convergent synthesis of triazole dendrimers. 
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Figure 3.8 continued. 
 
TEG and HEG glycols, which they then applied to the syntheses of PEG chains of 
variable lengths (Figure 3.9).111  Frechet and co-workers utilized poly(vinylacetylene)  
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Figure 3.9 Route to small PEG oligomers. 
 
and click chemistry to synthesize linear “dendrimer-like” polymers.112  They were able to 
repeat the click reactions making up to, but not including, fourth generation dendrons 
(Figure 3.10).112   
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Figure 3.10 Route to first generation dendronized linear polymers. 
 
With the recent trend in mind, the linkers were fathomed to be variable lengths of 
TEG and HEG components constructed utilizing iterative “click” reactions.  Since these 
are designed to use in bivalent peptidomimetics mimicking neurotrophins, the various 
distances between the hot spots on the proteins were considered (Figure 3.11).  Linkers   
must be able to span the minimum distance of about 20 Å  to a maximum of about 60 Å.   
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Figure 3.11 Distances between various hot spots (highlighted in yellow) on NGF. 
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Although the linkers are not meant to be implemented as they are shown below, they are 
plausible starting points for the actual linkers that will be incorporated into the bivalent 
peptidomimetics (Figure 3.12).  The TEG linkers seem to match the distances on NGF 
 
 
O
O
N
NN
O
O
O
NN
O
O
NN
O
O
O
O S
O
O
42 Å
O
O
N
NN
O
O
ON
O
O
O S
O
O
27 Å
O
O
N
NN
O
O
O
NN
O
O
NN
O
O
O
O S
O
O
2
57 Å
HO
O
O
OH
11 Å
TEG
 
 
 
O
O
O
O
O
OHHO
21 Å
HEG
 
 
 
Figure 3.12 Measured distances of the various TEG and HEG linkers. 
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Figure 3.12 continued. 
 
well, while HEG linkers are too long.  An important fact to keep in mind about these 
linkers is the extended form may not be the preferred conformation, therefore HEG 
linkers might prove to be more useful than they originally seem. 
3.2.3 Syntheses of Linkers 
Retrosynthetic analysis of the various linkers indicated the starting materials 
should be compounds A, 4, 12, and 16 (Scheme 3.1).  However, Dr. Genliang Lu 
discovered that compound A was difficult to synthesize on a large scale and the purity  
was poor.  Thus, it was substituted with a more UV active compound 5 (Figure 3.13).   
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Scheme 3.1 Original synthetic scheme to TEG and HEG linkers of variable lengths. 
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Figure 3.13 Structure of compound 5, a substitute for compound A. 
 
Compound 5 is a more synthetically attractive compound than A because it could easily 
be visualized under the UV lamp, thus avoiding the need for chemical stains when 
monitoring reactions, and it is easier to purify chromatographically because of the 
relatively non-polar isoindoline-1,3-dione component.  With the new modification, the 
original synthetic scheme was changed to accommodate the TEG linker synthesis 
(Scheme 3.2).  Even though compound 12 could be modified to maintain consistency,  
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Scheme 3.2 Modified synthetic scheme for synthesis of TEG linkers. 
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compound A was modified when work had already begun on the HEG linker following 
the original scheme.    
 The iterative syntheses of the TEG linkers begin with the syntheses of compounds 
 
Scheme 3.3 Synthetic route to compound 5. 
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4 and 5.  Dr. Lu performed the synthesis of compound 5, which begins with nucleophilic 
substitution of the chlorine on 2-(2-(2-chloroethoxy)ethoxy)ethanol with the 
commercially-available potassium salt of isoindoline-1,3-dione, tosylation of the 
hydroxyl group, and displacement of the tosylate by an azide nucleophile afforded the 
product with an overall yield of 86% (Scheme 3.3).  Compound 4 was synthesized in four 
steps beginning with monoprotection of TEG using TBDMS-Cl, alkylation using 
propargyl bromide, deprotection of the silyl group using TBAF, and finally tosylation of 
the free hydroxyl group to yield the desired product (Scheme 3.4).113-115  Combining 4   
 
Scheme 3.4 Synthetic route to compound 4. 
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and 5 in the presence of copper(II) with the reducing agent sodium ascorbate yielded the 
desired compound 6 (Scheme 3.5).112  The click condition was chosen based on a 
conceptually similar use in the literature by Frechet and co-workers with their synthesis 
of dendronized linear polymers.112  Another condition used was the generation of Cu(I) in 
situ by the comproportionation of Cu(0) and Cu(II) in t-BuOH and water (1:1)116 which 
produced the triazole product with no improvement in yield.  For the sake of consistency 
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Scheme 3.5 Synthetic route to compound 6. 
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and to potentially avoid any side reactions with the sodium ascorbate reductant, the Fokin 
method was used for the all subsequent click reactions.  Compound 6 was converted to 7 
simply by refluxing sodium azide in acetonitrile (Scheme 3.6).117  Compound 7 was then    
reacted with compound 4 to yield compound 8 (Scheme 3.7).116  The dramatic decrease in 
 
Scheme 3.6 Synthetic route to compound 7. 
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Scheme 3.7 Synthetic route to compound 8. 
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yield can be attributed to the difficulty collecting all the product during the purification 
step.  In addition, as the shear size and bulkiness of the reagents increase, the azide and 
alkyne functionalities are more shielded from each other, thereby preventing the 
cycloaddition process.112  Compounds 9 and 10 were synthesized using the previous 
reaction conditions for the syntheses of compounds 7 and 8, respectively, with the 
exception for the synthesis of 10 which ran for 48 hours (Scheme 3.8).116,117   
 
Scheme 3.8 Synthetic routes to compounds 9 and 10. 
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Scheme 3.8 continued. 
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The iterative syntheses of HEG linkers begin with the syntheses of compounds 12 
and 16.  Compound 12 was obtained in two steps: monotosylation of HEG using the 
Hii111 method and alkylation with propargyl bromide (Scheme 3.9).113  The  
 
Scheme 3.9 Synthetic routes to compounds 11 and 12. 
 
O O O OTs
4
HO
O O OH
4
TsCl
Ag2O, KI
CH2Cl2
HO O O OTs
4
NaH, THF
-5 oC to 40 oC
22 h
Br
11
89%
12
46%
 
 
monotosylation developed by Hii was adopted because it was a mild, high-yielding, and 
high-purity procedure, avoiding the classical approach of using pyridine.  The synthesis 
of 16 required four steps.  HEG was ditosylated to give 13.118  The tosylates were then 
displaced with azides to give 14.113,119  Monoreduction of one azide functionality gave 
15120 and protection of the amine group with tert-butylcarbonate (BOC)121 afforded the 
desired starting material 16 (Scheme 3.10).  Compounds 12 and 16 were reacted using the    
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Scheme 3.10 Synthetic routes to compounds 13, 14, 15, and 16. 
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same conditions as in the first click reaction of the TEG linker synthesis for the sake of 
consistency (Scheme 3.11).112  Note that the yields for 6 and 17 are comparable. 
 
Scheme 3.11 Synthetic route to compound 17. 
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Compound 17 was refluxed with sodium azide in acetonitrile117 to give 18, which was 
used to react with 12 in the presence of Cu(I) generated by comproportionation of Cu(0) 
and Cu(II)116 to give 19 (Scheme 3.12).  Finally, the tosylate on 19 was substituted with     
 
Scheme 3.12 Synthetic routes to compounds 18 and 19. 
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an azide117 to give 20, which was reacted with 12 in the presence of Cu(I)116 to give the 
third iterative HEG linker 21 (Scheme 3.13).  The yield obtained for 21 is similar to that  
 
Scheme 3.13 Synthetic routes to compounds 20 and 21. 
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Scheme 3.13 continued. 
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obtained for 10.  In general, the purities and yields for TEG linkers are better than those 
for HEG linkers.  
3.2.4 Application of TEG/HEG Units to 3’-O-Protected Nucleotide Triphosphates 
One of the many methods currently available for DNA sequencing is the Base 
Addition Sequencing Scheme (BASS).  Crucial to this technique is a set of four 
nucleotide bases blocked at the 3’ position that are fluorescent and labile.122  Burgess and 
co-workers had synthesized a library of 3’-O-labile nucleotide protecting groups and 
discovered that the nucleotide with the o-nitrobenzyl functionality had significant 
incorporation and could easily be removed by irradiating at 350 nm.122  The other 
protecting groups were not incorporated and some had solubility problems.122  A 
plausible solution would be to modify the nitrobenzyl template using TEG or HEG units 
to improve water-solubility (Figure 3.14).  Compound 24 emerged as an initial target, 
which could easily be modified later by changing the HEG unit.  The synthesis of 24  
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Figure 3.14 Structure of a 3’-O-2-nitrobenzyl nucleotide (left). TP represents a 
triphosphate group. Modified 3’-O-protecting group incorporating a HEG unit (right). 
 
begins with the alkylation of vanillin using propargyl bromide to give 22,123 then 
stepwise nitration and reduction of the aldehyde122 to give 23.  Compound 23 was then 
reacted with 16 using Cu(0) and Cu(II)116 to yield 24 (Scheme 3.14).  
 
Scheme 3.14 Synthetic routes to compounds 22, 23, and 24. 
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3.2.5 Application of TEG/HEG Units to Isoelectric Point (pI) Markers 
A potentially interesting application of the TEG and HEG linkers is in isoelectric 
focusing (IEF).  IEF is a method by which proteins are separated and characterized by 
their overall net charges, which are zeroes at their respective pIs.124  Unlike the standard 
SDS-PAGE technique, the pH in IEF is not kept constant.124  Instead, the proteins move 
against a pH-gradient until they reach a certain pH where their charges are zero (pH = 
pI).124  Therefore, to characterize and separate proteins or other amphoteric analytes, the 
pH at the focusing point must be known.125  Often reference standards, such as pI makers, 
are used to help determine the pH.125  Low-molecular mass compounds125 and peptides126 
have been used as pI markers.  Although triazoles (pKa ~ 14)127 can be protonated 
relatively easily with weak to mild acids in aqueous solutions, 1,4-substituted triazoles  
require much stronger acidic conditions for protonation.128  Abboud and co-workers 
experimentally determined that 1-methyl-4-phenyltriazole had a pKBH+ of 0.05 in 
aqueous media.128  Therefore, only very strong acids such as hydrobromic acid (pKa ~      
-9), perchloric acid (pKa ~ -10), and trifluoromethanesulfonic acid (pKa ~ -3) can 
completely protonate 1,4-substituted triazole derivatives.  Nonetheless, Figure 3.15 
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Figure 3.15 A hypothetical relationship between charge and pH of a TEG linker. 
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shows a hypothetical situation in which a TEG linker—with the appropriate 
modifications—can serve as a pI marker.  In a strongly acidic medium, all three triazoles 
would be protonated.  As the pH is increased, the charge on the linker decreases.  Thus, a 
relationship between charge on the linker and pH of the aqueous environment can be 
established.  Even though the linkers are far from being useful pI markers for protein 
purification applications, with some modifications and exploratory experimentations, 
they may become conceptual realities. 
3.3 Results and Discussion 
Indeed, the utilities of the TEG and HEG linkers extend beyond the realm of 
serving as merely water-soluble spacers in bivalent peptidomimetic constructions.  
Although the yields (and the purities, especially for the HEG linkers) from the syntheses 
of the linker molecules are not quite up to par as reported in the literature for the click 
reactions, they are tolerable nevertheless.  Gauging the purities of these linkers by NMR 
could be misleading.  Some of these compounds may seem clean by NMR, but not so by 
HPLC.  For example, the 1H NMR spectrum for compound 16 seems to suggest high 
purity but that is not the case by HPLC, which indicates an 82% purity.  Despite the 
slight setback, these linker molecules, however, could be obtained in gram-quantities.  
TEG and HEG are relatively cheap, commercially-available starting materials.  Simply 
scaling-up the click reactions would provide enough TEG and HEG linkers for exploring 
whatever applications a creative mind may conjure. 
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CHAPTER IV 
CONCLUSION 
 A small set of molecules designed to mimic the N-terminus of NGF has been 
studied computationally.  They were all docked successfully onto TrkA.  However, 
successful docking does not simply imply they are all primed candidates and should be 
synthesized and tested.  Likewise, those that did not “fit” well should not be blindly 
discarded.  Modifications to the structures can be made and the compounds studied again.  
Designing new mimics is a very time-consuming process.  α-helices are not trivial targets 
to mimic for two reasons.  First, the attribute of the “helix conformation” is difficult to 
“design” into a molecule mimic because it is not a low energy conformation.  Molecules 
do not have the propensity to adopt it unless restraints are in place.  Second, the designs 
available in the literature are few and relatively complex with various restraints to hold 
the molecule in a helix conformation.  As research continues in this area, every molecular 
design should be cherished and regarded as special. 
 A set of TEG and HEG linkers for use in constructing bivalent peptidomimetics 
has been synthesized.  These linkers serve dual roles. First, they can increase the water-
solubility of the bivalent peptidomimetics and, second, they can act as spacer units 
spanning the distances between the critical hot spots on proteins.  In addition, their water-
soluble attribute can be applied in making 3’-O-nucleotide protecting groups and pI 
markers.  These linkers can be obtained relatively easy and in large  amounts.  Generally 
speaking, the purities for most of the linkers are good, more so for the TEG linkers than 
the HEG linkers.  Considering that the starting units for TEG and HEG linker syntheses 
are not consistent, the purity for HEG linkers can be improved by using the isoindoline-
1,3-dione moiety instead of the BOC for compound 16.  Also, the synthetic scheme of 12 
can be modified to give a purer compound—perhaps monoprotection/deprotection like in 
the synthesis of 4.  Whether making nucleotide protecting groups or pI markers or 
optimizing conditions to get purer linkers, further work in this area, it seems, is 
inevitable. 
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APPENDIX A 
 
CHAPTER II EXPERIMENTAL PROCEDURES 
 
Docking Protocol.  Docking calculations were performed on a Silicon Graphics O2 
workstation with an IRIX 6.3 operating system using InsightII suite of programs 
developed by Accelrys.  Simulations were carried out using the CVFF method.   
The receptor was loaded in PDB format and hydrogens were displayed. The pH 
was set to 7 and charged.  Water was unmerged and removed from the receptor.  The 
force field potentials were fixed and checked for any incomplete valencies.  The receptor 
file was then saved as a .CAR file.   
The ligand was loaded and saved as a .CAR file.   
The receptor and ligand were loaded onto the same screen.  The docking assembly 
was created with the “Associate” menu option.  The assembly was given a name.  The 
site where the ligand will be placed and docked was defined under the “Subset” and 
“Interface” menu options.  The radius of the subset was defined to be 10 squared 
angstroms. 
The side-chains on the ligand molecules were each oriented in a way that is the 
most similar to the crystal structure H4 and I6 of NGF interacting with TrkA.  Docking 
was carried out in the “Docking” and “Affinity” options in the MSI module.  A grid for 
the “bulk” atoms was first carried out, then the potential energy of the docking assembly 
was minimized with a minimum of 1000 steps.  The best minimized complex was 
selected and displayed.  
The radius of the subset—i.e. the site on TrkA where the ligand molecule was 
docked—was converted to a Connolly surface, which is basically a potential surface, 
smoothed by rolling a water molecule along the desired area.  The calculation takes place 
under the “Molecule” and “Surface” menu options.    
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APPENDIX B 
 
CHAPTER III EXPERIMENTAL PROCEDURES 
 
General Methods.  Melting points were determined in capillary tubes with a MEL-
TEMPII apparatus by Laboratory Devices and are uncorrected. Nuclear Magnetic 
Resonance (NMR) spectra were recorded with a Mercury-300 (1H at 300 MHz, 13C NMR 
at 75 MHz) or Inova-500 (1H at 500 MHz, 13C NMR at 125 MHz) NMR spectrometers. 
Chemical shifts are reported in units of parts per million (ppm) relative to solvent 
(CDCl3: 7.27 ppm for 1H and 77.0 ppm for 13C).  Fourier Transform-Infrared (FT-IR) 
spectra were recorded with a Nicolet Impact 410 IR instrument using NaCl plates.  Mass 
spectra were obtained from the Laboratory for Biological Mass Spectrometry at Texas 
A&M University.  Thin layer chromatography was performed using silica gel 60 F254 
plates.  Flash chromatography was performed using ultra pure silica gel (40-63 µm 
particle size, 230-400 mesh).  Ether, THF, MeOH, CH2Cl2, and triethylamine were 
distilled from appropriate drying agents.  Analytical HPLC were run on a Scientific 
Systems, Inc. system (232C Gradient solvent module, 222C Pump) with a UV detector 
using a GraceVydac (cat. #101TP54, 4.6 x 250 mm) unbonded silica column.  Gradient 
elution was used (A = hexane or CHCl3, B = iPrOH) with a constant flow rate of 1.0 
mL/min.  Analytical HPLC were also run on a Beckman Coulter System Gold 125 
Solvent Module and Sedex 55 Detector using a GraceVydac (cat. #218TP54, 4.6 x 250 
mm) Protein and Peptide C18 column.  Gradient elution was used (A = water, B = 
MeCN, both with 0.1% v/v TFA) with a constant flow rate of 1.0 mL/min.  
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Compound 1 
2-(2-(2-(2-tert-Butyldimethylsilyloxy)ethoxy)ethoxy)ethanol113  
 
HO
O
O
O Si
 
 
Procedure: 
 Triethylene glycol (20.0 g, 133 mmol) and tert-butyldimethylsilyl chloride (22.1 
g, 146 mmol) were dissolved in 250 mL distilled CH2Cl2.  The mixture was cooled to 0 
oC in an ice bath. TEA (20.4 mL, 146 mmol) was added gradually followed by the 
addition of DMAP (1.62 g, 13.2 mmol).  The mixture was allowed to warm slowly to 
room temperature with stirring for 20 h.  The reaction mixture was washed with 0.1 M 
HCl (2 x 300 mL).  The acidic extracts were pooled and extracted with CH2Cl2 (1 x 200 
mL).  The combined organic extracts were evaporated under reduced pressure and 
purified by flash chromatography eluting first with 1:4 EtOAc/hexane then with 4:1 
EtOAc/hexane to afford 1 as a colorless oil (14.2 g, 40%).  1H NMR (CDCl3, 500 MHz): 
δ (ppm) 0.04 (s, 6H), 0.87 (s, 9H), 2.70 (br, 1H), 3.55 (t, J = 3.0 Hz, 2H), 3.58 (t, J = 7.0 
Hz, 2H), 3.64 (s, 4H), 3.70 (t, J = 4.8 Hz, 2H), 3.75 (t, J = 5.5 Hz, 2H); 13C NMR 
(CDCl3, 125 MHz): δ (ppm) 18.3, 25.8, 61.6, 62.6, 70.4, 70.7, 72.4, 72.6.  
 
 
 
 
 
 
 
 
 
 
 
 
 60 
 
1H NMR 
 
 
 
 
13C NMR 
 
 61 
Compound 2 
2-(2-(2-(Prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)tert-butyldimethylsilane113  
 
O
O
O
O Si
 
 
Procedure: 
 Sodium hydride (2.54 g, 63.5 mmol) was added scoop-wise to a solution 
containing compound 1 (14.0 g, 52.9 mmol) and 75 mL distilled THF at 0 oC under N2. 
After the evolution of hydrogen gas had ceased, the reaction flask was capped and 
propargyl bromide (11.8 g, 79.3 mmol) was syringed into the mixture slowly.  The 
reaction mixture was allowed to warm gradually to room temperature with stirring under 
N2 for 12 h.  Deionized water (200 mL) was then added to the mixture and extracted with 
CH2Cl2 (3 x 100 mL). The organic extracts were pooled, dried over Na2SO4, filtered and 
evaporated in vacuo.  The resulting residue was purified by flash chromatography using 
1:5 EtOAc/hexane, yielding 2 as a colorless oil (11.7 g, 73%).  1H NMR (CDCl3, 500 
MHz): δ (ppm) 0.06 (s, 6H), 0.89 (s, 9H), 2.42 (t, J = 2.5 Hz, 1H), 3.55 (t, J = 5.3 Hz, 
2H), 3.64-3.70 (m, 8H), 3.76 (t, J = 5.5 Hz, 2H), 4.20 (d, J = 2 Hz, 2H); 13C NMR 
(CDCl3, 125 MHz): δ (ppm) 18.3, 25.9, 58.3, 62.7, 69.0, 70.4, 70.6, 70.7, 72.6, 74.4, 
79.6. 
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Compound 3 
2-(2-(2-(Prop-2-ynyloxy)ethoxy)ethoxy)ethanol113 
 
O
O
O
HO
 
 
Procedure: 
 Method A: TBAF (77.0 mL, 77.0 mmol) was added to a solution containing 
compound 2 (11.7 g, 38.5 mmol) and 120 mL distilled THF at 0 oC under N2.  After the 
addition was completed, the ice-bath was removed and the solution stirred at room 
temperature for 1 h.  The reaction mixture was then evaporated in vacuo, yielding a wine-
red oil which was purified by flash chromatography using EtOAc to afford 3 as a yellow 
oil (6.27 g, 86%).  
 Method B: Sodium hydride (1.44 g, 36.0 mmol) was added scoop-wise to a 
solution containing triethylene glycol (15.0 g, 100. mmol) and 75 mL distilled THF at 0 
oC.  After the bubbling had ceased, the reaction flask was capped and the solution stirred 
under N2 for 0.5 h at 0 oC.  Propargyl bromide (7.44 g, 50.0 mmol) in 5 mL distilled THF 
was added slowly to the reaction flask via a syringe.  The mixture was warmed gradually 
to room temperature with stirring for 16 h.  DI water (150 mL) was added and extracted 
with CH2Cl2 (3 x 75 mL).  The organics were pooled, dried over Na2SO4 and 
concentrated under reduced pressure.  The residue was purified by flash chromatography 
eluting with 3:2 EtOAc/hexane to afford 3 as a yellow oil (4.01 g, 59%).  1H NMR 
(CDCl3, 500 MHz): δ (ppm) 2.43 (t, J = 2.5 Hz, 1H), 2.61 (s, 1H),  3.59 (t, J = 2.8 Hz, 
2H), 3.60-3.70 (m, 8H), 3.71 (t, J = 3.0 Hz, 2H), 4.19 (d, J = 2.5 Hz, 2H); 13C NMR 
(CDCl3, 125 MHz): δ (ppm) 58.3, 61.6, 69.0, 68.9, 70.2, 70.3, 72.4, 74.5, 79.5. 
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Compound 4 
2-(2-(2-(Prop-2-ynyloxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate 
 
O
O
O
OS
O
O
 
 
Procedure: 
 Compound 3 (10.3 g, 54.6 mmol), TEA (19.0 mL, 136 mmol), and 
trimethylamine hydrochloride (522 mg, 5.46 mmol) were dissolved in 140 mL MeCN at 
0 oC. p-Toluenesulfonyl chloride (20.8 g, 109 mmol) was added and the reaction mixture 
stirred at 0 oC for 50 minutes, then at room temperature for 30 minutes.  DI water (180 
mL) was added and extracted with EtOAc (3 x 150 mL).  The combined organics were 
dried over MgSO4, filtered, and concentrated in vacuo.  The resulting residue was 
purified by flash chromatography eluting first with 1:3 EtOAc/hexane then with 1:1 
EtOAc/hexane, yielding 4 as a yellow oil (16.2 g, 87%).  1H NMR (CDCl3, 500 MHz): 
δ (ppm) 2.43 (t, J = 2.5 Hz, 1H), 2.45 (s, 3H), 3.59 (s, 4H), 3.64-3.65 (m, 2H), 3.67-3.69 
(m, 4H), 4.15 (t, J = 5.0 Hz, 2H), 4.19 (d, J = 2 Hz, 2H), 7.34 (d, J = 8.5 Hz, 2H), 7.79 (d, 
J = 8.5 Hz, 2H); 13C NMR (CDCl3, 125 MHz): δ (ppm) 21.6, 58.3, 68.6, 69.1, 70.4, 70.5, 
70.7, 74.5, 79.6, 127.9, 129.8, 132.9, 144.7; MS (APCI, m/z) 365.1 for [M+Na]+. 
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Compound 5 
2-(2-(2-(2-Azidoethoxy)ethoxy)ethyl)isoindoline-1,3-dione 
 
O
O
N3N
O
O
 
 
Procedure: 
 Compound was obtained from Dr. Genliang Lu and purified by column 
chromatography eluting with 2:3 EtOAc/hexane to afford 5 as a light-yellow oil.  1H 
NMR (CDCl3, 500 MHz): δ (ppm) 3.30 (t, J = 5.3 Hz, 2H), 3.61 (dt, J = 6.0 Hz, 5.3 Hz, 
4H), 3.65 (dt, J = 5.0 Hz, 4.3 Hz, 2H), 3.75 (t, J = 5.6 Hz, 2H), 3.90 (t, J = 5.5 Hz, 2H), 
7.72 (dd, J = 7.0 Hz, 3.5 Hz, 2H), 7.85 (dd, J = 6.0 Hz, 3.0 Hz, 2H); 13C NMR (CDCl3, 
125 MHz): δ (ppm) 37.2, 50.6, 68.0, 70.0, 70.1, 70.6, 123.2, 132.1, 133.9, 168.2; MS 
(APCI/ESI, m/z) 327.1 for [M+Na]+. 
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Compound 6 
2-(2-(2-(2-(4-((2-(2-(2-(4-Methylbenzenesulfonyl)ethoxy)ethoxy)ethoxy)methyl)-1H-
1,2,3-triazol-1-yl)ethoxy)ethoxy)ethyl)isoindoline-1,3-dione 
 
O
O
N
NN
O
O
O
ON
O
O
S
O
O
 
 
Procedure: 
 Compound 4 (343 mg, 1.00 mmol) and compound 5 (305 mg, 1.00 mmol) were 
mixed together in 3.5 mL THF in a scintillation vial at room temperature.  An equal 
amount of DI water (3.5 mL) was then added with vigorous stirring.  10 mol% sodium 
ascorbate and  5 mol% CuSO4.5H2O were added from freshly prepared 1 M aqueous 
solutions.  The vial was capped and stirred for 20 h at room temperature. The mixture 
was then filtered through a pad of silica gel and washed with 600 mL EtOAc.  The 
organic wash was evaporated in vacuo and purified by flash chromatography eluting first 
with 3:1 EtOAc/hexane then with MeOH, yielding 6 as a pale-yellow oil (446 mg, 69%). 
Rf  = 0.28 (EtOAc); 1H NMR (CDCl3, 500 MHz): δ (ppm) 2.45 (s, 3H), 3.56-3.58 (m, 
4H), 3.60 (s, 4H), 3.61-3.64 (m, 2H), 3.67-3.70 (m, 4H), 3.72 (t, J = 5.8 Hz, 2H), 3.80 (t, 
J = 5.0 Hz, 2H), 3.90 (t, J = 5.8 Hz, 2H), 4.15 (t, J = 5.0 Hz, 2H), 4.46 (t, J = 5.3 Hz, 2H), 
4.68 (s, 2H), 7.34 (d, J = 8.5 Hz, 2H), 7.73 (dd, J = 6.0 Hz, 3.0 Hz, 2H), 7.75 (s, 1H), 
7.79 (d, J = 8.5 Hz, 2H), 7.85 (dd, J = 6.0 Hz, 3.0 Hz, 2H); 13C NMR (CDCl3, 125 MHz): 
δ (ppm) 21.6, 37.2, 50.2, 50.8, 64.4, 68.0, 68.6, 69.2, 69.4, 69.6, 69.9, 70.47, 70.49, 70.5, 
70.7, 123.2, 123.9, 127.9, 129.8, 132.0, 132.9, 134.0, 144.8, 168.2; MS (ESI, m/z) 647.2 
for [M+H]+. 
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Compound 7 
2-(2-(2-(2-(4-((2-(2-(2-Azidoethoxy)ethoxy)ethoxy)methyl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethyl)isoindoline-1,3-dione 
 
O
O
N
NN
O
O
O
N3N
O
O
 
 
Procedure: 
 Compound 6 (1.10 g, 1.70 mmol) and sodium azide (0.222 g, 3.41 mmol) were 
refluxed in 12 mL MeCN for 40 h.  DI water (40 mL) was added and extracted with 
CH2Cl2 (4 x 40 mL).  The organic extracts were pooled, dried over Na2SO4, filtered, and 
evaporated in vacuo, yielding 7 as a yellow oil (814 mg, 93%). 1H NMR (CDCl3, 500 
MHz): δ (ppm) 3.37 (t, J = 5.3 Hz, 2H), 3.55 (t, J = 2.5 Hz, 2H), 3.60 (t, J = 4.3 Hz, 2H), 
3.65-3.72 (m, 12H), 3.79 (t, J = 5.0 Hz, 2H), 3.89 (t, J = 5.8 Hz, 2H), 4.45 (t, J = 5.0 Hz, 
2H), 4.67 (s, 2H), 7.71 (dd, J = 6.0 Hz, 3.0 Hz, 2H), 7.73 (s, 1H), 7.83 (dd, J = 6.0 Hz, 
3.0 Hz, 2H); 13C NMR (CDCl3, 125 MHz): δ (ppm) 37.1, 50.1, 50.6, 64.4, 67.9, 69.4, 
69.6, 69.8, 69.9, 70.4, 70.52, 70.53, 70.6, 123.2, 123.8, 132.0, 134.0, 144.8, 168.2; MS 
(MALDI, m/z) 540.2 for [M+Na]+. 
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Compound 8 
2-(2-(2-(2-(4-((2-(2-(2-(4-((2-(2-(2-(4-Methylbenzenesulfonyl) 
ethoxy)ethoxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)methyl)- 
1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethyl)isoindoline-1,3-dione 
 
O
O
N
NN
O
O
ON
O
O 2
O S
O
O
 
 
Procedure: 
 Compound 7 (777 mg, 1.50 mmol), compound 4 (514 mg, 1.50 mmol), copper 
powder (191 mg, 3.00 mmol), and 600 µL of an aqueous 1M CuSO4.5H2O solution (40 
mol%) were suspended in 5 mL tBuOH/H2O (1:1) mixture in a scintillation vial.  The vial 
was capped and the reaction solution stirred vigorously for 12 h at room temperature.  It 
was diluted with 25 mL EtOAc and filtered through a pad of silica gel.  The silica was 
washed with 5% MeOH/EtOAc (500 mL).  The organic washings were combined and 
evaporated under reduced pressure, yielding 8 as a viscous, yellow oil (368 mg, 29%). 
TLC shows one spot, but NMR indicates presence of impurities.  Rf  = 0.33 (10% 
MeOH/EtOAc); 1H NMR (CDCl3, 500 MHz): δ (ppm) 2.43 (s, 3H), 3.55-3.74 (m, 22H), 
3.80 (t, J = 5.0 Hz, 2H), 3.87 (t, J = 5.0 Hz, 2H), 3.89 (t, J = 5.8 Hz, 2H), 4.12-4.20 (m, 
4H), 4.47 (t, J = 5.0 Hz, 2H ), 4.54 (br, 2H), 4.67 (s, 2H), 4.68 (s, 2H), 7.33 (d, J = 8.5 
Hz, 2H), 7.72 (dd, J = 6.0 Hz, 3.5 Hz, 2H), 7.74 (s, 1H), 7.79 (d, J = 9.0 Hz, 2H), 7.78 (s, 
1H), 7.84 (dd, J = 6.0 Hz, 3.0 Hz, 2H); 13C NMR (CDCl3, 125 MHz): δ (ppm) 21.6, 37.2, 
50.2, 58.4, 64.4, 68.0, 68.6, 69.0, 69.20, 69.24, 69.4, 69.6, 69.9, 70.43, 70.47, 70.50, 
70.51, 70.7, 123.2, 127.9, 129.8, 132.0, 132.9, 134.0, 144.8, 168.2, some signals account 
for more than one carbon; MS (MALDI, m/z) 860.4 for [M+H]+. 
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Compound 9 
2-(2-(2-(2-(4-((2-(2-(2-(4-((2-(2-(2-Azidoethoxy)ethoxy)ethoxy)methyl)-1H-1,2,3-
triazol-1-yl)ethoxy)ethoxy)ethoxy)methyl)- 1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethyl)isoindoline-1,3-dione 
 
O
O
N
NN
O
O
ON
O
O 2
N3
 
 
Procedure: 
 Compound 8 (356 mg, 0.410 mmol) and sodium azide (87.0 mg, 1.34 mmol) were 
refluxed in 5 mL MeCN for 40 h.  DI water (20 mL) was added and extracted with 
CH2Cl2 (5 x 20 mL).  The organic extracts were pooled, dried over Na2SO4, filtered, and 
evaporated in vacuo, yielding 9 as a yellow oil (265 mg, 88%). 1H NMR (CDCl3, 500 
MHz): δ (ppm) 3.38 (t, J = 5.3 Hz, 2H), 3.56 (t, J = 4.8 Hz, 2H), 3.61-3.74 (m, 22H), 
3.80 (t, J = 5.3 Hz, 2H), 3.87 (t, J = 4.8 Hz, 2H), 3.90 (t, J = 5.8 Hz, 2H), 4.46 (t, J = 5.0 
Hz, 2H), 4.53 (t, J = 4.8 Hz, 2H), 4.68 (s, 4H), 7.20 (dd, J = 6.5 Hz, 3.5 Hz, 2H), 7.76 (s, 
1H), 7.77 (s, 1H), 7.84 (dd, J = 5.5 Hz, 3.0 Hz, 2H); 13C NMR (CDCl3, 125 MHz): 
δ (ppm) 37.2, 50.3, 50.6, 64.5, 68.0, 69.4, 69.6, 69.65, 69.9, 70.0, 70.45, 70.48, 70.51, 
70.52, 70.58, 70.6, 70.7, 123.2, 132.0, 134.0, 168.2, some signals account for more than 
one carbon; MS (MALDI, m/z) 731.4 for [M+H]+. 
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Compound 10 
2-(2-(2-(2-(4-((2-(2-(2-(4-((2-(2-(2-(4-((2-(2-(2-(4-Methylbenzenesulfonyl) 
ethoxy)ethoxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)methyl)- 
1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)methyl)- 1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethyl)isoindoline-1,3-dione 
 
O
O
N
NN
O
O
ON
O
O 3
O S
O
O
 
 
Procedure: 
 Compound 9 (255 mg, 0.350 mmol), compound 4 (120. mg, 0.350 mmol), copper 
powder (45 mg, 0.70 mmol), and 140 µL of an aqueous 1M CuSO4.5H2O solution (40 
mol%) were suspended in 2 mL tBuOH/H2O (1:1) mixture in a scintillation vial.  The vial 
was capped and the reaction solution stirred vigorously for 48 h at room temperature.  
The product was purified by flash chromatography eluting first with 10% MeOH/EtOAc, 
then with 50% MeOH/EtOAc, yielding 10 as a dull-yellow oil (143 mg, 38%). 1H NMR 
(CDCl3, 500 MHz): δ (ppm) 2.44 (s, 3H), 3.54-3.72 (m, 34H), 3.79 (t, J = 5.0 Hz, 2H), 
3.85 (t, J = 5.3 Hz, 2H), 3.89 (t, J = 5.5 Hz, 2H), 4.13 (t, J = 6.8 Hz, 2H), 4.45 (t, J = 5.3 
Hz, 2H), 4.51 (t, J = 5.3 Hz, 4H), 4.65 (s, 4H), 4.66 (s, 2H), 7.33 (d, J = 8.5 Hz, 2H), 7.71 
(dd, J = 6.5 Hz, 3.5 Hz, 2H), 7.72 (s, 2H), 7.74 (s, 1H), 7.78 (d, J = 8.5 Hz, 2H), 7.83 (dd, 
J = 6.5 Hz, 3.5 Hz, 2H); 13C NMR (CDCl3, 125 MHz): δ (ppm) 21.6, 37.2, 50.1, 64.4, 
64.5, 67.9, 68.6, 69.2, 69.4, 69.5, 69.8, 70.3, 70.40, 70.44, 70.45, 70.5, 70.7, 123.2, 123.8, 
127.9, 129.8, 132.0, 132.9, 134.0, 144.6, 144.7, 168.2, some signals account for more 
than one carbon; MS (MALDI, m/z) 1095.5 for [M+Na]+. 
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Compound 11 
2-(2-(2-(2-(2-(2-Hydroxylethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl 4-
methylbenzenesulfonate111 
 
O
O
O
O
O
O OHS
O
O
 
 
Procedure: 
 Hexaethylene glycol (5.66 g, 20.0 mmol) was solubilized in 400 mL CH2Cl2 and 
cooled to 0 oC.  Silver(I) oxide (6.96 g, 30.0 mmol) was added and the mixture stirred for 
about 10 minutes followed by sequential additions of p-toluenesulfonyl chloride (4.20 g, 
22.0 mmol) and potassium iodide (0.660 g, 4.00 mmol).  The reaction stirred for 20 
minutes and filtered through celite, washing with EtOAc.  The organic washings was 
evaporated in vacuo and the resulting residue purified by flash chromatography using 1:1 
EtOAc/ acetone to afford 11 as a colorless oil (7.80 g, 89%).  1H NMR (CDCl3, 300 
MHz): δ (ppm) 2.35 (s, 3H), 3.15 (s, 1H), 3.47-3.62 (m, 22H), 4.05 (t, J = 5.7 Hz, 2H), 
7.25 (d, J = 8.1 Hz, 2H), 7.68 (d, J = 8.4 Hz, 2H); 13C NMR (CDCl3, 75 MHz): δ (ppm) 
21.2, 61.1, 68.2, 69.0, 69.8, 70.07, 70.1, 70.2, 72.1, 127.5, 129.5, 132.5, 144.4, some 
signals account for more than one carbon.  
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Compound 12 
2-(2-(2-(2-(2-(2-Prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl 4-
methylbenzenesulfonate 
 
O
O
O
O
O
O OS
O
O
 
 
Procedure: 
 Compound 11 (4.56 g, 10.5 mmol) and propargyl bromide (3.11 g, 20.9 mmol) 
was mixed in 50 mL distilled THF at -5 oC.  After the scoop-wise addition of sodium 
hydride (0.275 g, 11.5 mmol), the reaction flask was capped and stirred under N2 
allowing the yellowish-orange solution to warm gradually to room temperature.  The 
reaction mixture was then gently heated to 40 oC, stirring for 22 h. DI water (150 mL) 
was added and extracted with CH2Cl2 (3 x 100 mL).  The combined organic extracts were 
dried over Na2SO4 and evaporated under reduced pressure.  The crude product was 
purified by column chromatography eluting with 1:1 EtOAc/acetone to yield 12 as a 
yellow oil (2.26 g, 46%).  HPLC (1:1 MeCN/H2O with 0.1% TFA): retention time 18.8 
minutes, purity 86%; 1H NMR (CDCl3, 500 MHz): δ (ppm) 2.42 (t, J = 2.0 Hz, 1H), 2.43 
(s, 3H), 3.45 (t, J = 6.5 Hz, 2H), 3.48-3.70 (m, 20H), 3.80 (t, J = 6.5 Hz, 2H), 4.19 (d, J = 
2.5 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 7.78 (d, J = 8.0 Hz, 2H); 13C NMR (CDCl3, 125 
MHz): δ (ppm) 21.6, 30.3, 58.3, 68.6, 69.0, 69.2, 70.3, 70.43, 70.46, 70.48, 70.51, 70.53, 
70.6, 70.7, 71.1, 79.6, 127.9, 129.7, 132.9, 144.7; MS (ESI, m/z) 481.2 for [M+Li]+.  
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Compound 13 
1-(2-(2-(2-(2-(2-(4-Methylbenzenesulfonyloxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy) 
ethyl 4-methylbenzenesulfonate118 
 
O
O
O
O
O
O O SS
O
O
O
O
 
 
Procedure: 
 Hexaethylene glycol (27.9 g, 98.9 mmol) and p-toluenesulfonyl chloride (56.6 g, 
296 mmol) were dissolved in 150 mL THF.  The mixture was cooled to 0 oC and 
potassium hydroxide (42 mL of a 16 M solution) was added very slowly.  The reaction 
solution was allowed to warm to room temperature and stirred for 8 h after which it was 
poured into 300 mL of a 2:1 CH2Cl2/ice-water mixture and extracted with CH2Cl2 (3 x 
200 mL).  The pooled organic extracts were washed with 2M KOH (2 x 200 mL), brine 
(2 x 200 mL), and water (6 x 200 mL).  The extracts were dried over MgSO4, filtered, and 
evaporated in vacuo, yielding 13 as a yellow oil (49.2 g, 84%).  1H NMR (CDCl3, 300 
MHz): δ (ppm) 2.34 (s, 6H), 3.47 (s, 8H), 3.51 (s, 8H), 3.57 (t, J = 4.8 Hz, 4H), 4.05 (t, J 
= 4.7 Hz, 4H), 7.25 (d, J = 8.4 Hz, 4H), 7.68 (d, J = 8.1 Hz, 4H); 13C NMR (CDCl3, 75 
MHz): δ (ppm) 21.1, 68.1, 69.0, 69.9, 70.0, 70.1, 127.4, 129.4, 132.4, 144.4, some signals 
account for more than one carbon.  
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Compound 14 
1-(2-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)-2-azidoethane113 
 
O
O
O
O
O
N3 N3
 
 
Procedure: 
 Compound 13 (36.2 g, 61.3 mmol) and sodium azide (15.9 g, 245 mmol) were 
refluxed in 600 mL MeCN for 43 h.  DI water (600 mL) was added and extracted with 
CH2Cl2 (3 x 200 mL).  The combined organic extracts were dried over Na2SO4, decanted, 
and evaporated under reduced pressure, yielding 14 as a pale-orange oil (18.6 g, 91%). 1H 
NMR (CDCl3, 300 MHz): δ (ppm) 3.23 (t, J = 5.1 Hz, 4H), 3.51-3.55 (m, 20H); 13C 
NMR (CDCl3, 75 MHz): δ (ppm) 50.0, 69.4, 69.9, 69.99, 70.02, some signals account for 
more than one carbon.  
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Compound 15 
2-(2-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethanamine120 
 
O
O
O
O
O
H2N N3
 
 
Procedure: 
 Compound 14 (18.6 g, 56.0 mmol) was solubilized in 150 mL 0.65M H3PO4. 
Triphenylphosphine (12.2 g, 46.7 mmol) in 50 mL anhydrous ether was added drop-wise 
using an addition funnel over a period of 20 minutes.  The funnel was rinsed with 20 mL 
ether and the washing added to the reaction mixture.  The reaction flask was capped and 
stirred at room temperature for 24 h under N2.  The reaction solution was then washed 
with ether (3 x 50 mL) to get rid of triphenylphosphine oxide.  Potassium hydroxide 
powder (16 g) was added slowly with gentle swirling (caution: exothermic reaction!). 
More triphenylphosphine oxide was observed crystallizing out.  The ether was allowed to 
slowly evaporate at room temperature, further inducing more triphenylphosphine oxide to 
crystallize out into the aqueous layer.  The flask was then capped tightly and stored at -5 
oC to -10 oC for 12 h to induce even more triphenylphosphine oxide crystallizations.  The 
white solid was then filtered and potassium hydroxide powder (30 g) was added and 
extracted with CH2Cl2 (12 x 50 mL).  The combined organic extracts were dried over 
Na2SO4, filtered, and evaporated in vacuo, yielding 15 as a yellow liquid (11.5 g, 67%).  
1H NMR (CDCl3, 300 MHz): δ (ppm) 2.53 (br, 2H), 3.06 (t, J = 5.1 Hz, 2H), 3.18 (t, J = 
5.3 Hz, 2H), 3.29-3.38 (m, 20H); 13C NMR (CDCl3, 75 MHz): δ (ppm) 40.9, 49.8, 69.1, 
69.4, 69.65, 69.68, 69.72, 69.75, 72.5, some signals account for more than one carbon. 
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Compound 16 
2-(2-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl tert-butylcarbamate 
 
O
O
O
O
O
N
H
O
O
N3
 
 
Procedure: 
 Compound 15 (13.2 g, 43.2 mmol) and di-tert-butylcarbonate (9.42 g, 43.2 mmol) 
were dissolved in 100 mL CH2Cl2 at room temperature.  NaOH (1.40 g, 35.0 mmol) was 
added and the reaction mixture stirred for 4 h.  The cloudy solution was filtered through 
celite and evaporated in vacuo.  The product residue was purified by column 
chromatography using EtOAc, yielding 16 as a yellow oil (6.36 g, 50%).  HPLC (1:1 
MeCN/H2O with 0.1% TFA): retention time 17.1 minutes, purity 82%; Rf  = 0.68 
(EtOAc); 1H NMR (CDCl3, 500 MHz): δ (ppm) 1.39 (s, 9H), 3.25 (br, 2H), 3.33 (t, J = 
5.0 Hz, 2H), 3.48 (t, J = 5.3 Hz, 2H), 3.55-3.63 (m, 18H), 5.10 (br, 1H); 13C NMR 
(CDCl3, 125 MHz): δ (ppm) 28.2, 40.2, 50.5, 69.9, 70.02, 70.05, 70.3, 70.39, 70.4, 70.43, 
70.48, 70.5, 78.9, 155.8, some signals account for more than one carbon; MS (ESI, m/z) 
429.2 for [M+Na]+. 
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Compound 17 
2-(2-(2-(2-(2-(2-4-((2-(2-(2-(2-(2-(2-(4-Methylbenzenesulfonyloxy)ethoxy)ethoxy) 
ethoxy)ethoxy)ethoxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy) 
ethoxy)ethoxy)ethyl tert-butylcarbamate 
 
N
H
O
O
N
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O
O
O
O
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O
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Procedure: 
 Compound 12 (237 mg, 0.50 mmol) and compound 16 (203 mg, 0.50 mmol) were 
mixed together in 1.5 mL THF/H2O mixture in a scintillation vial at room temperature. 
10 mol% sodium ascorbate and 5 mol% CuSO4.5H2O were added from freshly prepared 1 
M aqueous solutions.  The vial was capped and stirred vigorously for 24 h at room 
temperature.  Column chromatography using 1:1 EtOAc/ acetone afforded a clear, yellow 
oil (270 mg, 61%).  1H NMR (CDCl3, 300 MHz): δ (ppm) 1.43 (s, 9H), 2.44 (s, 3H), 3.31 
(t, J = 5.3 Hz, 2H), 3.53 (t, J = 5.3 Hz, 2H), 3.57-3.69 (m, 38H), 3.86 (t, J = 5.1 Hz, 2H), 
4.15 (t, J = 5.6 Hz, 2H), 4.53 (t, J = 5.1 Hz, 2H), 4.67 (s, 2H), 5.10 (br, 1H), 7.35 (d, J = 
8.7 Hz, 2H), 7.75 (s, 1H), 7.79 (d, J = 8.4 Hz, 2H); 13C NMR (CDCl3, 75 MHz): δ (ppm) 
21.6, 28.4, 40.3, 50.2, 64.5, 68.6, 69.2, 69.4, 69.5, 70.1, 70.2, 70.4, 70.5, 70.7, 71.2, 
123.8, 125.9, 127.9, 129.8, 132.9, 144.76, 144.8, some signals account for more than one 
carbon; MS (APCI, m/z) 881.2 for [M+H]+. 
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Compound 18 
2-(2-(2-(2-(2-(2-4-((2-(2-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethoxy)ethoxy) 
ethoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy) ethoxy)ethoxy)ethyl  
tert-butylcarbamate 
 
N
H
O
O
N
4
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O
O
O
N3
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Procedure: 
 Compound 17 (52.7 mg, 60 µmol) and sodium azide (10.0 mg, 0.15 mmol) were 
refluxed in 4 mL MeCN for 32 h.  DI water (6 mL) was added and extracted with CH2Cl2 
(5 x 10 mL).  The organic extracts were pooled, dried over Na2SO4, filtered, and evapo-
rated under reduced pressure, yielding 18 as a yellow oil (34.7 mg, 77%).  1H NMR 
(CDCl3, 500 MHz): δ (ppm) 1.43 (s, 9H), 3.30 (t, J = 5.0 Hz, 2H), 3.38 (t, J = 5.0 Hz, 
2H), 3.52 (t, J = 5.0 Hz, 2H), 3.60 (m, 38H), 3.86 (t, J = 5.0 Hz, 2H), 4.52 (t, J = 5.0 Hz, 
2H), 4.67 (s, 2H), 5.09 (br, 1H), 7.74 (s, 1H); 13C NMR (CDCl3, 125 MHz): δ (ppm) 
28.4, 40.3, 50.1, 50.6, 64.5, 69.4, 69.6, 69.96, 70.15, 70.18, 70.41, 70.44, 70.50, 70.51, 
70.56, 70.59, 70.62, 123.7, 144.8, some signals account for more than one carbon; IR 
(film): ν (cm-1) 1702, 2095, 2916, 3345; MS (ESI, m/z) 752.4 for [M+H]+. 
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Compound 19 
2-(2-(2-(2-(2-(2-(4-((2-(2-(2-(2-(2-(2-4-((2-(2-(2-(2-(2-(2-(4-Methylbenzenesulfonyl 
oxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy) ethoxy)methyl)-1H-1,2,3-triazol-1-yl) 
ethoxy)ethoxy)ethoxy) ethoxy)ethoxy)ethoxy)methyl)- 1H-1,2,3-triazol-1-yl) ethoxy) 
ethoxy)ethoxy)ethoxy)ethoxy)ethyl tert-butylcarbamate 
 
N
H
O
O
N
4
NN
O
O
O
O
4
O
O
S
O
O
2
 
 
Procedure: 
 Compound 18 (328 mg, 0.440 mmol), compound 12 (207 mg, 0.440 mmol), 
copper powder (140. mg, 2.20 mmol), and 800 µL of an aqueous 1M CuSO4.5H2O 
solution (40 mol%) were suspended in 10 mL tBuOH/H2O (1:1) mixture in a scintillation 
vial.  The vial was capped and the reaction solution stirred vigorously for 64 h at room 
temperature.  The mixture was filtered through celite and washed with MeOH and 
evaporated under reduced pressure.  The residue was diluted with CH2Cl2 and washed 
with brine/EDTA solution (1 x 60 mL) and evaporated under reduced pressure.  The 
crude product was purified by flash chromatography eluting first with EtOAc/acetone 
(1:1) then with MeOH, yielding 19 as a yellow oil (296 mg, 55%).  1H NMR (CDCl3, 500 
MHz): δ (ppm) 1.38 (s, 9H), 2.39 (s, 3H), 3.25 (t, J = 5.0 Hz, 2H), 3.47 (t, J = 5.0 Hz, 
2H), 3.52-3.64 (m, 58H), 3.81 (t, J = 5.0 Hz, 4H), 4.09 (t, J = 4.8 Hz, 2H), 4.47 (t, J = 5.3 
Hz, 4H), 4.61 (s, 4H), 5.05 (br, 1H), 7.29 (d, J = 8.5 Hz, 2H), 7.69 (s, 2H), 7.73 (d, J = 
8.5 Hz, 2H); 13C NMR (CDCl3, 125 MHz): δ (ppm) 21.4, 28.2, 30.2, 40.1, 50.0, 53.3, 
64.3, 68.4, 69.1, 69.3, 69.4, 69.99, 70.26, 70.28, 70.3, 70.34, 70.5, 70.97, 78.9, 123.6, 
127.8, 129.6, 132.7, 144.6, 144.64, 155.8, some signals account for more than one 
carbon; MS (MALDI, m/z) 1248.8 for [M+Na]+. 
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Compound 20 
2-(2-(2-(2-(2-(2-(4-((2-(2-(2-(2-(2-(2-4-((2-(2-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy) 
ethoxy)ethoxy) ethoxy)methyl)-1H-1,2,3-triazol-1-yl) ethoxy)ethoxy)ethoxy)ethoxy) 
ethoxy)ethoxy)methyl)- 1H-1,2,3-triazol-1-yl) ethoxy)ethoxy)ethoxy)ethoxy)ethoxy) 
ethyl tert-butylcarbamate 
 
N
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Procedure: 
 Compound 19 (296 mg, 0.24 mmol) and sodium azide (50.0 mg, 0.77 mmol) were 
refluxed in 5 mL MeCN for 41 h.  DI water (15 mL) was added and extracted with 
CH2Cl2 (4 x 20 mL).  The organic extracts were pooled, dried over Na2SO4, filtered, and 
evaporated under reduced pressure, yielding 20 as a yellow oil (216 mg, 82%).  1H NMR 
(CDCl3, 500 MHz): δ (ppm) 1.44 (s, 9H), 3.30 (t, J = 5.0 Hz, 2H), 3.38 (t, J = 5.0 Hz, 
2H), 3.48 (s, 2H), 3.53 (t, J = 5.0 Hz, 2H), 3.60-3.70 (m, 56H), 3.87 (t, J = 5.0 Hz, 4H), 
4.53 (t, J = 5.3 Hz, 4H), 4.67 (s, 4H), 5.10 (br, 1H), 7.74 (s, 1H), 7.75 (s, 1H); 13C NMR 
(CDCl3, 125 MHz): δ (ppm) 28.4, 40.3, 50.2, 50.6, 64.5, 69.4, 69.58, 69.59, 69.99, 70.18, 
70.2, 70.3, 70.43, 70.47, 70.5, 70.57, 70.61, 70.64, 123.8, 125.9, 128.3, 128.5, 144.7, 
some signals account for more than one carbon; MS (MALDI, m/z) 1119.6 for [M+Na]+. 
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Compound 21 
2-(2-(2-(2-(2-(2-(4-((2-(2-(2-(2-(2-(2-(4-((2-(2-(2-(2-(2-(2-4-((2-(2-(2-(2-(2-(2-(4-
Methylbenzenesulfonyloxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy) ethoxy)methyl)-
1H-1,2,3-triazol-1-yl) ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)methyl)-1H-1,2,3-
triazol-1-yl)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)methyl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl tert-butylcarbamate 
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Procedure: 
 Compound 20 (202 mg, 0.18 mmol), compound 12 (87.0 mg, 0.18 mmol), copper 
powder (23.0 mg, 0.36 mmol), and 80 µL of an aqueous 1M CuSO4.5H2O solution (40 
mol%) were suspended in 1.5 mL tBuOH/H2O (1:1) mixture in a scintillation vial.  The 
vial was capped and the reaction solution stirred vigorously for 48 h at room temperature. 
The reaction was diluted with EtOAc and filtered through celite.  The crude product was 
purified by column chromatography eluting first with 10% MeOH/EtOAc then with 50% 
MeOH/EtOAc, yielding 21 as a light-yellow gel (87 mg, 30%).  1H NMR (CDCl3, 500 
MHz): δ (ppm) 1.40 (s, 9H), 2.41 (s, 3H), 3.26 (t, J = 5.0 Hz, 4H), 3.49 (t, J = 5.0 Hz, 
4H), 3.53-3.69 (m, 74H), 3.83 (t, J = 4.8 Hz, 6H), 4.11 (t, J = 4.8 Hz, 2H), 4.49 (t, J = 4.8 
Hz, 6H), 4.63 (s, 2H), 4.64 (s, 2H), 4.65 (s, 2H), 5.12 (br, 1H), 7.30 (d, J = 8 Hz, 2H), 
7.72 (s, 3H), 7.75 (d, J = 7.5 Hz, 2H); 13C NMR (CDCl3, 125 MHz): δ (ppm) 21.9, 28.6, 
40.5, 50.3, 50.4, 61.6, 64.7, 68.9, 69.5, 69.55, 69.7, 69.8, 70.3, 70.4, 70.55, 70.6, 70.7, 
70.9, 72.7, 72.74, 124.07, 124.1, 128.2, 130.1, 145.0, some signals account for more than 
one carbon; MS (MALDI, m/z) 1593.8 for [M+Na]+. 
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Compound 22 
3-methoxy-4-(prop-2-ynyloxy)benzaldehyde123  
 
 
H3CO
O
O
 
 
Procedure: 
 Vanillin (15.2 g, 100. mmol) and potassium carbonate (13.8 g, 100. mmol) were 
dissolved in 300 mL acetone. The mixture was stirred for 0.5 h at room temperature. 
Propargyl bromide (15.6 g, 105 mmol) mixed with 50 mL acetone was then added 
gradually to the reaction solution. The mixture was refluxed for 24 h, after which 400 mL 
DI H2O was added to precipitate the product 22 as a light-yellow solid (16.8 g, 88%). 1H 
NMR (CDCl3, 300 MHz): δ (ppm) 2.57 (t, J = 2.3 Hz, 1H), 3.94 (s, 3H), 4.86 (d, J = 2.4 
Hz, 2H), 7.14 (d, J = 8.4 Hz, 1H), 7.45 (d, J = 7.2 Hz, 1H), 7.48 (s, 1H), 9.87 (s, 1H); 13C 
NMR (CDCl3, 75 MHz): δ (ppm) 55.99, 56.54, 76.64, 77.39, 109.38, 112.50, 126.24, 
130.87, 149.97, 152.06, 190.86.  
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Compound 23 
5-methoxy-2-nitro-4-(prop-2-ynyloxy)phenyl methanol  
 
 
H3CO
O
HO
NO2
 
 
Procedure: 
 Compound 22 (16.8 g, 88.6 mmol) in 75 mL of acetic anhydride was added 
slowly to a thoroughly chilled solution of concentrated nitric acid (300 mL) and  acetic 
anhydride (125 mL) in an ice-bath. The mixture was stirred for 2 h at 0 oC, then 2 h at 
room temperature. It was diluted with 1.2 L EtOAc, washed with brine (1 x 1 L), 
saturated NaHCO3 solution (3 x 1 L), and brine again (2 x 1 L). The resulting organic 
layer was dried over Na2SO4 and filtered through a pad of silica gel over celite, washing 
with plenty of EtOAc. Evaporation under reduced pressure afforded the nitrated product 
as an orange solid, which was dissolved in 675 mL absolute EtOH and chilled to 0 oC. 
Sodium borohydride (7.56 g, 200. mmol) was added scoop-wise to the chilled mixture. 
The reaction was allowed to gradually warm to room temperature then quenched with 
100 mL saturated NH4Cl solution. It was diluted with 1 L EtOAc then washed with DI 
H2O (1 x 1 L) and brine (1 x 1 L). The organic phase was dried over Na2SO4, filtered, and 
evaporated in vacuo. The crude product was purified by flash chromatography using 1:1 
EtOAc/hexane to yield 23 as a yellow solid (12.8 g, 61%  – 2 steps); m.p. 126-131 oC; 1H 
NMR (CDCl3, 300 MHz): δ (ppm) 2.59 (t, J = 2.6 Hz, 1H), 4.01 (s, 3H), 4.84 (d, J = 2.4 
Hz, 2H), 4.99 (s, 2H), 7.23 (s, 1H), 7.89 (s, 1H); 13C NMR (CDCl3, 75 MHz): δ (ppm) 
56.47, 57.05, 62.77, 77.11, 110.97, 111.34, 133.34, 145.48, 154.47; MS (APCI, m/z) 
238.0 for [M+H]+. 
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Compound 24 
2-(2-(2-(2-(2-(2-(4-((4-(Hydroxymethyl)-2-methoxy-5-nitrophenoxy)methyl)-1H-
1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl tert-butylcarbamate 
 
 
H3CO
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Procedure: 
 Compound 23 (237 mg, 1.00 mmol), compound 16 (407 mg, 1.00 mmol), copper 
powder (50.0 mg, 0.787 mmol), and 200. µL of an aqueous 1M CuSO4.5H2O solution (40 
mol%) were mixed together in 14 mL tBuOH/H2O (1:1) mixture in a scintillation vial. 
The reaction mixture was stirred for 24 h at room temperature then purified by flash 
chromatography eluting with 1:3 MeOH/acetone to give 24 as a yellow oil (186 mg, 
29%); 1H NMR (CDCl3, 300 MHz): δ (ppm) 1.34 (s, 9H), 3.20 (t, J = 5.4 Hz, 2H), 3.44 
(t, J = 3.8 Hz, 2H), 3.49-3.57 (m, 18H),  3.80 (t, J = 4.8 Hz, 2H), 3.85 (s, 2H), 4.48 (t, J = 
5.1 Hz, 2H), 4.91 (s, 2H), 5.16 (s, 3H), 7.29 (s, 1H), 7.73 (s, 1H), 7.87 (s, 1H); 13C NMR 
(CDCl3, 75 MHz): δ (ppm) 28.07, 40.01, 50.05, 56.00, 61.37, 62.61, 68.96, 69.84, 70.04, 
70.11, 70.15, 109.89, 109.97, 124.47, 134.37, 138.36, 142.21, 145.58, 154.12, 155.81; 
MS (ESI, m/z) 666.3 [M+Na]+. 
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